Literature DB >> 26335534

Investigating short-term toxicity of melphalan in a model of an isolated and superfused bovine retina.

Kai Januschowski1,2, Carlo Krupp3, Sebastian Mueller3, Kathleen Hofmann3, Sven Schnichels3, Ulrike Hagemann3, Martin S Spitzer3, Karl-Ulrich Bartz-Schmidt3, Sabine Aisenbrey4.   

Abstract

BACKGROUND: Melphalan, as a treatment for retinoblastoma, has been applied intra-arterially by catheterisation of the ophthalmic artery or intravitreally, aiming to reduce systemic side effects of intravenous drug therapy. This study evaluates retinal toxicity of different melphalan concentrations measured by electroretinogram (ERG) in an isolated and perfused retinal whole mount culture.
METHODS: For functional testing, bovine retinas were prepared and perfused with an oxygen-saturated standard solution and the ERG was recorded until stable b-wave or a-wave amplitudes were reached. Thereafter, retinae were exposed to 80, 160 and 320 μg/ml of melphalan for 30 min. After exposure, a washout was performed thrice for 5 min each and the ERG amplitude recovery was monitored for 60 min. To investigate the effects on photoreceptor function, 1-mM asparate was added to suppress the b-wave and obtain isolated a-waves.
RESULTS: While no toxic effects for a concentration of 80 μg/ml were observed, both b- and a-waves were significantly reduced after application of 160 (b-wave 43.8 %, p = 0.03; a-wave 28.2 %, p = 0.04) and 320 μg/ml (b-wave 20.0 %, p = 0.04; a-wave 35.8 %, p = 0.02). For 320 μg/ml, this reduction remained significant at the end of the washout (b-wave 40.0 % p = 0.02; a-wave 26.4 %, p = 0.02).
CONCLUSIONS: Epiretinal or intraretinal concentrations of 80-μg/ml melphalan do not cause toxic effects in this in vitro model. Concentrations higher than 160 μg/ml should be avoided.

Entities:  

Keywords:  Electroretinogram; Melphalan; Retina; Retinal toxicity; Retinoblastoma

Mesh:

Substances:

Year:  2015        PMID: 26335534     DOI: 10.1007/s00417-015-3149-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  22 in total

1.  Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma.

Authors:  Francis L Munier; Maja Beck-Popovic; Aubin Balmer; Marie-Claire Gaillard; Etienne Bovey; Stefano Binaghi
Journal:  Retina       Date:  2011-03       Impact factor: 4.256

2.  Testing the biocompatibility of a glutathione-containing intra-ocular irrigation solution by using an isolated perfused bovine retina organ culture model - an alternative to animal testing.

Authors:  Kai Januschowski; Ahmad Zhour; Albert Lee; Ramin Maddani; Sebastien Mueller; Martin S Spitzer; Sven Schnichels; Maximilian Schultheiss; Deshka Doycheva; Karl-Ulrich Bartz-Schmidt; Peter Szurman
Journal:  Altern Lab Anim       Date:  2012-03       Impact factor: 1.303

3.  Superselective catheterization of the ophthalmic artery for intraarterial chemotherapy for retinoblastoma.

Authors:  Carol L Shields; Aparna Ramasubramanian; Robert Rosenwasser; Jerry A Shields
Journal:  Retina       Date:  2009-09       Impact factor: 4.256

Review 4.  Current concepts for diagnosis and treatment of retinoblastoma in Germany: aiming for safe tumor control and vision preservation.

Authors:  P Temming; D Lohmann; N Bornfeld; W Sauerwein; S L Goericke; A Eggert
Journal:  Klin Padiatr       Date:  2012-11-09       Impact factor: 1.349

5.  Evaluating retinal toxicity of a new heavy intraocular dye, using a model of perfused and isolated retinal cultures of bovine and human origin.

Authors:  Kai Januschowski; Sebastian Mueller; Martin S Spitzer; Charlotte Schramm; Deshka Doycheva; Karl-Ulrich Bartz-Schmidt; Peter Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-28       Impact factor: 3.117

6.  Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.

Authors:  Francis L Munier; Marie-Claire Gaillard; Aubin Balmer; Sameh Soliman; Gregory Podilsky; Alexandre P Moulin; Maja Beck-Popovic
Journal:  Br J Ophthalmol       Date:  2012-06-13       Impact factor: 4.638

7.  Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.

Authors:  Jasmine H Francis; Paula Schaiquevich; Emiliano Buitrago; María José Del Sole; Gustavo Zapata; J Oscar Croxatto; Brian P Marr; Scott E Brodie; Alejandro Berra; Guillermo L Chantada; David H Abramson
Journal:  Ophthalmology       Date:  2014-05-10       Impact factor: 12.079

8.  Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Eur J Cancer Clin Oncol       Date:  1982-04

Review 9.  Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor?

Authors:  Dan S Gombos; John Hungerford; David H Abramson; Judith Kingston; Guillermo Chantada; Ira J Dunkel; Celia B G Antoneli; Mark Greenwald; Barret G Haik; Carlos A Leal; Aurora Medina-Sanson; Amy C Schefler; Gavivann Veerakul; Regina Wieland; Norbert Bornfeld; Mathew W Wilson; Christopher Bing On Yu
Journal:  Ophthalmology       Date:  2007-07       Impact factor: 12.079

Review 10.  Conservative treatment modalities in retinoblastoma.

Authors:  Bhavna Chawla; Amit Jain; Rajvardhan Azad
Journal:  Indian J Ophthalmol       Date:  2013-09       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.